Trial · NCT01854918
Results by group40
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 40
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Adverse Events | Year 1: Standard of Care | All adverse events | 796 | Participants | |
| Number of Participants With Adverse Events | Year 1: Evolocumab + Standard of Care | All adverse events | 1655 | Participants | |
| Number of Participants With Adverse Events | Years 2-3: SOC / Evolocumab + SOC | All adverse events | 929 | Participants | |
| Number of Participants With Adverse Events | Years 2-3: Evolocumab + SOC / Evolocumab + SOC | All adverse events | 1789 | Participants | |
| Number of Participants With Adverse Events | Year 1: Standard of Care | Adverse events ≥ grade 2 | 519 | Participants | |
| Number of Participants With Adverse Events | Year 1: Evolocumab + Standard of Care | Adverse events ≥ grade 2 | 1070 | Participants | |
| Number of Participants With Adverse Events | Years 2-3: SOC / Evolocumab + SOC | Adverse events ≥ grade 2 | 700 | Participants | |
| Number of Participants With Adverse Events | Years 2-3: Evolocumab + SOC / Evolocumab + SOC | Adverse events ≥ grade 2 | 1339 | Participants | |
| Number of Participants With Adverse Events | Year 1: Standard of Care | Adverse events ≥ grade 3 | 124 | Participants | |
| Number of Participants With Adverse Events | Year 1: Evolocumab + Standard of Care | Adverse events ≥ grade 3 | 225 | Participants | |
| Number of Participants With Adverse Events | Years 2-3: SOC / Evolocumab + SOC | Adverse events ≥ grade 3 | 214 | Participants | |
| Number of Participants With Adverse Events | Years 2-3: Evolocumab + SOC / Evolocumab + SOC | Adverse events ≥ grade 3 | 379 | Participants | |
| Number of Participants With Adverse Events | Year 1: Standard of Care | Adverse events ≥ grade 4 | 7 | Participants | |
| Number of Participants With Adverse Events | Year 1: Evolocumab + Standard of Care | Adverse events ≥ grade 4 | 17 | Participants | |
| Number of Participants With Adverse Events | Years 2-3: SOC / Evolocumab + SOC | Adverse events ≥ grade 4 | 11 | Participants | |
| Number of Participants With Adverse Events | Years 2-3: Evolocumab + SOC / Evolocumab + SOC | Adverse events ≥ grade 4 | 35 | Participants | |
| Number of Participants With Adverse Events | Year 1: Standard of Care | Serious adverse events | 104 | Participants | |
| Number of Participants With Adverse Events | Year 1: Evolocumab + Standard of Care | Serious adverse events | 195 | Participants | |
| Number of Participants With Adverse Events | Years 2-3: SOC / Evolocumab + SOC | Serious adverse events | 178 | Participants | |
| Number of Participants With Adverse Events | Years 2-3: Evolocumab + SOC / Evolocumab + SOC | Serious adverse events | 332 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01854918/results